NRBO News and Press, NeuroBo Pharmaceuticals Inc. From 06/14/21

JuSun/iStock via Getty Images NeuroBo Pharmaceuticals ([[NRBO]] +31.8%) is on course to witness its biggest one-day gain in more than a year today. Last week, the company announced an upcoming Special Meeting scheduled to seek stockholder approval for the issuance of common stock. The of...

NeuroBo Pharmaceuticals (NRBO): Q1 GAAP EPS of -$0.15 beats by $0.01.Cash and Cash Equivalents were $13MPress Release For further details see: NeuroBo Pharmaceuticals EPS beats by $0.01

NeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results PR Newswire BOSTON , May 17, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal di...

NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) traded at a new 52-week low today of $3.33. Approximately 1.1 million shares have changed hands today, as compared to an average 30-day volume of 213,000 shares. NeuroBo Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is en...

Shares of NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) traded today at $3.20, breaking its 52-week low. So far today approximately 1.1 million shares have been exchanged, as compared to an average 30-day volume of 213,000 shares. Potential upside of 65.6% exists for NeuroBo Pharmaceuticals...

Gainers: Purple Biotech (PPBT) +9%, NeuroBo Pharmaceuticals (NRBO) +7%, Obalon Therapeutics (OBLN) +7%, Dare Bioscience (DARE) +4%, Hoth Therapeutics (HOTH) +2%.Losers: Syndax Pharmaceuticals (SNDX) -28%, Zai Lab (ZLAB) -13%, KalVist...

NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) traded at a new 52-week low today of $3.17. So far today approximately 1.1 million shares have been exchanged, as compared to an average 30-day volume of 213,000 shares. NeuroBo Pharmaceuticals Inc. share prices have moved between a 52-week high...

NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update Acquisition of ANA Therapeutics provides late-stage COVID-19 clinical development program with numerous key inflection points in 2021 PR Newswire BOSTON , A...

Penny stocks are well-known for their high risk and potential for high reward. Because of that, many advisors suggest that this type of investment only take a small portion of your overall holdings. Some top financial firms have a rule of thumb that 10% or less is a good benchmark for high-...

NeuroBo Pharmaceuticals (NRBO) perks up 6% premarket after receiving approval of an amendment to its Contingent Value Rights ((CVR)) agreement from a majority of CVR holders. The CVRs were distributed to the holders of Gemphire Therapeutics (GEMP) common stock on December 30, 2019, ...